Vitamin D and Cardiovascular Disease
dc.contributor.author | Nemerovski, Carrie W. | en_US |
dc.contributor.author | Dorsch, Michael P | en_US |
dc.contributor.author | Simpson, Robert U. | en_US |
dc.contributor.author | Bone, Henry G. | en_US |
dc.contributor.author | Aaronson, Keith D. | en_US |
dc.contributor.author | Bleske, Barry E. | en_US |
dc.date.accessioned | 2012-03-16T15:57:53Z | |
dc.date.available | 2012-03-16T15:57:53Z | |
dc.date.issued | 2009-06 | en_US |
dc.identifier.citation | Nemerovski, Carrie W.; Dorsch, Michael P; Simpson, Robert U.; Bone, Henry G.; Aaronson, Keith D.; Bleske, Barry E. (2009). "Vitamin D and Cardiovascular Disease." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29(6). <http://hdl.handle.net/2027.42/90252> | en_US |
dc.identifier.issn | 0277-0008 | en_US |
dc.identifier.issn | 1875-9114 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90252 | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Vascular Disease | en_US |
dc.subject.other | 1,25‐Dihydroxyvitamin D | en_US |
dc.subject.other | 1,25(OH) 2 D | en_US |
dc.subject.other | 25‐Hydroxyvitamin D | en_US |
dc.subject.other | 25(OH)D | en_US |
dc.subject.other | Cardiology | en_US |
dc.subject.other | Cardiovascular Disease | en_US |
dc.subject.other | Heart Failure | en_US |
dc.subject.other | Hypertension | en_US |
dc.subject.other | Vitamin D | en_US |
dc.title | Vitamin D and Cardiovascular Disease | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Internal Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Internal Medicine, Divisions of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Cardiology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Michigan Bone and Mineral Clinic, P.C., Detroit, Michigan. | en_US |
dc.identifier.pmid | 19476421 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90252/1/phco.29.6.691.pdf | |
dc.identifier.doi | 10.1592/phco.29.6.691 | en_US |
dc.identifier.source | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | en_US |
dc.identifier.citedreference | Giovannucci, E., Liu, Y., Hollis, B.W., Rimm, E.B.. 25‐Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168: 1174 – 80. | en_US |
dc.identifier.citedreference | Kristal‐Boneh, E., Froom, P., Harari, G., Ribak, J.. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997; 30: 1289 – 94. | en_US |
dc.identifier.citedreference | Scragg, R., Holdaway, I., Singh, V., Metcalf, P., Baker, J., Dryson, E.. Serum 25‐hydroxycholecalciferol concentration in newly detected hypertension. Am J Hypertens 1995; 8: 429 – 32. | en_US |
dc.identifier.citedreference | Scragg, R., Sowers, M.F., Bell, C.. Serum 25‐hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. Am J Hypertens 2007; 20: 713 – 19. | en_US |
dc.identifier.citedreference | Snijder, M.B., Lips, P., Seidell, J.C., et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population‐based study in older men and women. J Intern Med 2007; 261: 558 – 65. | en_US |
dc.identifier.citedreference | Forman, J.P., Giovannucci, E., Holmes, M.D., et al. Plasma 25‐hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063 – 9. | en_US |
dc.identifier.citedreference | Sugden, J.A., Davies, J.I., Witham, M.D., Morris, A.D., Struthers, A.D.. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008; 25: 320 – 5. | en_US |
dc.identifier.citedreference | Pfeifer, M., Begerow, B., Minne, H.W., Nachtigall, D., Hansen, C.. Effects of a short‐term vitamin D 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633 – 7. | en_US |
dc.identifier.citedreference | Melamed, M.L., Muntner, P., Michos, E.D., et al. Serum 25‐hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 2008; 28: 1179 – 85. | en_US |
dc.identifier.citedreference | Targher, G., Bertolini, L., Padovani, R., et al. Serum 25‐hydroxyvitamin D3 concentrations and carotid artery intima‐media thickness among type 2 diabetic patients. Clin Endocrinol 2006; 65: 593 – 7. | en_US |
dc.identifier.citedreference | Lindén, V.. Vitamin D and myocardial infarction. Br Med J 1974; 3: 647 – 50. | en_US |
dc.identifier.citedreference | Lund, B., Badskjaer, J., Lund, B.J., Soerensen, O.H.. Vitamin D and ischaemic heart disease. Horm Metab Res 1978; 10: 553 – 6. | en_US |
dc.identifier.citedreference | Schmidt‐Gayk, H., Goossen, J., Lendle, F., Seidel, D.. Serum 25‐hydroxycalciferol in myocardial infarction. Atherosclerosis 1977; 26: 55 – 8. | en_US |
dc.identifier.citedreference | Vik, B., Try, K., Thelle, D.S., Forde, O.H.. Tromsø heart study: vitamin D metabolism and myocardial infarction [short report]. Br Med J 1979; 2: 176. | en_US |
dc.identifier.citedreference | Cigolini, M., Iagulli, M.P., Miconi, V., et al. Serum 25‐hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722 – 4. | en_US |
dc.identifier.citedreference | Wang, T.J., Pencina, M.J., Booth, S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503 – 11. | en_US |
dc.identifier.citedreference | Dobnig, H., Pilz, S., Scharnagl, H., et al. Independent association of low serum 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D levels with all‐cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340 – 9. | en_US |
dc.identifier.citedreference | Autier, P., Gandini, S.. Vitamin D supplementation and total mortality: a meta‐analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730 – 7. | en_US |
dc.identifier.citedreference | Melamed, M.L., Michos, E.D., Post, W., Astor, B.. 25‐Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629 – 37. | en_US |
dc.identifier.citedreference | Hsia, J., Heiss, G., Ren, H., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846 – 54. | en_US |
dc.identifier.citedreference | National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington DC: National Osteoporosis Foundation; 2008. | en_US |
dc.identifier.citedreference | Boxer, R.S., Dauser, D.A., Walsh, S.J., Hager, W.D., Kenny, A.M.. The association between vitamin D and inflammation with the 6‐minute walk and frailty in patients with heart failure. J Am Geriatr Soc 2008; 56: 454 – 61. | en_US |
dc.identifier.citedreference | Arroyo, M., Laguardia, S.P., Bhattacharya, S.K., et al. Micronutrients in African‐Americans with decompensated and compensated heart failure. Transl Res 2006; 148: 301 – 8. | en_US |
dc.identifier.citedreference | Laguardia, S.P., Dockery, B.K., Bhattacharya, S.K., Nelson, M.D., Carbone, L.D., Weber, K.T.. Secondary hyperparathyroidism and hypovitaminosis D in African‐Americans with decompensated heart failure. Am J Med Sci 2006; 332: 112 – 18. | en_US |
dc.identifier.citedreference | Shane, E., Mancini, D., Aaronson, K., et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997; 103: 197 – 207. | en_US |
dc.identifier.citedreference | Zittermann, A., Schleithoff, S.S., Tenderich, G., Berthold, H.K., Koerfer, R., Stehle, P.. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105 – 12. | en_US |
dc.identifier.citedreference | Zittermann, A., Schleithoff, S.S., Gotting, C., et al. Poor outcome in end‐stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008; 10: 321 – 7. | en_US |
dc.identifier.citedreference | Pilz, S., Marz, W., Wellnitz, B., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross‐sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93: 3927 – 35. | en_US |
dc.identifier.citedreference | Schleithoff, S.S., Zittermann, A., Tenderich, G., Berthold, H.K., Stehle, P., Koerfer, R.. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double‐blind, randomized, placebo‐controlled trial. Am J Clin Nutr 2006; 83: 754 – 9. | en_US |
dc.identifier.citedreference | Lonn, E., Yusuf, S., Arnold, M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567 – 77. | en_US |
dc.identifier.citedreference | Manson, J.E., Hsia, J., Johnson, K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523 – 34. | en_US |
dc.identifier.citedreference | Rossouw, J.E., Prentice, R.L., Manson, J.E.. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465 – 77. | en_US |
dc.identifier.citedreference | Waters, D.D., Alderman, E.L., Hsia, J., et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432 – 40. | en_US |
dc.identifier.citedreference | Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360: 23 – 33. | en_US |
dc.identifier.citedreference | Hathcock, J.N., Shao, A., Vieth, R., Heaney, R.. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85: 6 – 18. | en_US |
dc.identifier.citedreference | Wootton, A.M.. Improving the measurement of 25‐hydroxyvitamin D. Clin Biochem Rev 2005; 26: 33 – 6. | en_US |
dc.identifier.citedreference | Shoback, D., Sellmeyer, D., Bikle, D.. Greenspan's basic and clinical endocrinology, 8th ed. Columbus, OH: The McGraw‐Hill Companies, 2007. | en_US |
dc.identifier.citedreference | Holick, M.F.. Vitamin D deficiency. N Engl J Med 2007; 357: 266 – 81. | en_US |
dc.identifier.citedreference | Wikvall, K.. Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (review). Int J Mol Med 2001; 7: 201 – 9. | en_US |
dc.identifier.citedreference | Li, Y.C., Qiao, G., Uskokovic, M., Xiang, W., Zheng, W., Kong, J.. Vitamin D: a negative endocrine regulator of the renin‐angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89–90: 387 – 92. | en_US |
dc.identifier.citedreference | Zhou, C., Assem, M., Tay, J.C., et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug‐induced osteomalacia. J Clin Invest 2006; 116: 1703 – 12. | en_US |
dc.identifier.citedreference | Holick, M.F., Chen, T.C.. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008; 87: S1080 – 6. | en_US |
dc.identifier.citedreference | Holick, M.F.. Vitamin D status: measurement, interpretation, and clinical application [published online ahead of print March 8, 2008]. Ann Epidemiol 2008. Available from http:dx.doi.org10.1016j.annepidem.2007.12.001. | en_US |
dc.identifier.citedreference | Heaney, R.P.. Vitamin D endocrine physiology. J Bone Miner Res 2007; 22: V25 – 7. | en_US |
dc.identifier.citedreference | Heaney, R.. Vitamin D and calcium interactions: functional outcomes. Am J Clin Nutr 2008; 88 ( suppl ): S541 – 4. | en_US |
dc.identifier.citedreference | Janssen, H.C.. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002; 75: 611 – 15. | en_US |
dc.identifier.citedreference | Webb, A.R., Kline, L., Holick, M.F.. Influence of season and latitude on the cutaneous synthesis of vitamin D 3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D 3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373 – 8. | en_US |
dc.identifier.citedreference | Weishaar, R.E., Kim, S.N., Saunders, D.E., Simpson, R.U.. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990; 258: E134 – 42. | en_US |
dc.identifier.citedreference | Weishaar, R.E., Simpson, R.U.. Vitamin D3 and cardiovascular function in rats. J Clin Invest 1987; 79: 1706 – 12. | en_US |
dc.identifier.citedreference | Weishaar, R.E., Simpson, R.U.. Involvement of vitamin D3 with cardiovascular function II. Direct and indirect effects. Am J Physiol Endocrinol Metab 1987; 253: E675 – 83. | en_US |
dc.identifier.citedreference | Zittermann, A., Schleithoff, S.S., Koerfer, R.. Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev 2006; 11: 25 – 33. | en_US |
dc.identifier.citedreference | Rostand, S.G., Drueke, T.B.. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383 – 92. | en_US |
dc.identifier.citedreference | Park, C.W., Oh, Y.S., Shin, Y.S., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73 – 81. | en_US |
dc.identifier.citedreference | Shoji, T., Shinohara, K., Kimoto, E., et al. Lower risk for cardiovascular mortality in oral 1‐alpha‐hydroxy vitamin D 3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179 – 84. | en_US |
dc.identifier.citedreference | Teng, M., Wolf, M., Ofsthun, M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115 – 25. | en_US |
dc.identifier.citedreference | Drüeke, T., Fleury, J., Toure, Y., et al. Effect of parathyroidectomy on left‐ventricular function in haemodialysis patients. Lancet 1980; 1: 112 – 14. | en_US |
dc.identifier.citedreference | Gafter, U., Battler, A., Eldar, M., et al. Effect of hyperparathyroidism on cardiac function in patients with end‐stage renal disease. Nephron 1985; 41: 30 – 3. | en_US |
dc.identifier.citedreference | DeLuca, H.F.. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80: S1689 – 96. | en_US |
dc.identifier.citedreference | Nibbelink, K.A., Tishkoff, D.X., Hershey, S.D., Rahman, A., Simpson, R.U.. 1,25(OH) 2 ‐vitamin D 3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL‐1 cardiac myocyte. J Steroid Biochem Mol Biol 2007; 103: 533 – 7. | en_US |
dc.identifier.citedreference | Walters, M.R., Ilenchuk, T.T., Claycomb, W.C.. 1,25‐dihydroxyvitamin D3 stimulates 45Ca2 uptake by cultured adult rat ventricular cardiac muscle cells. J Biol Chem 1987; 262: 2536 – 41. | en_US |
dc.identifier.citedreference | Rahman, A., Hershey, S., Ahmed, S., Nibbelink, K., Simpson, R.U.. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007; 103: 416 – 19. | en_US |
dc.identifier.citedreference | Simpson, R.U., Hershey, S.H., Nibbelink, K.A.. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521 – 4. | en_US |
dc.identifier.citedreference | Xiang, W., Kong, J., Chen, S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin‐angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125 – 32. | en_US |
dc.identifier.citedreference | Li, Y.C., Kong, J., Wei, M., et al. 1,25‐dihydroxyvitamin D3 is a negative endocrine regulator of the renin‐angiotensin system. J Clin Invest 2002; 110: 229 – 38. | en_US |
dc.identifier.citedreference | Zittermann, A., Koerfer, R.. Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 2008; 29: 423 – 32. | en_US |
dc.identifier.citedreference | Mann, D.L., Young, J.B.. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994; 105: 897 – 904. | en_US |
dc.identifier.citedreference | Canning, M.O., Grotenhuis, K., Wit, H., Ruwhof, C., Drexhage, H.A.. 1‐alpha, 25‐dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001; 145: 351 – 7. | en_US |
dc.identifier.citedreference | Müller, K., Haahr, P.M., Diamant, M., Rieneck, K., Kharazmi, A., Bendtzen, K.. 1,25‐Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the posttranscriptional level. Cytokine 1992; 4: 506 – 12. | en_US |
dc.identifier.citedreference | Zhu, Y., Mahon, B.D., Froicu, M., Cantorna, T.. Calcium and 1‐alpha, 25‐dihydroxyvitamin D3 target the TNF‐alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35: 217 – 24. | en_US |
dc.identifier.citedreference | Duprez, D., Buyzere, M., Backer, T., Clement, D.. Relationship between vitamin D3 and the peripheral circulation in moderate arterial primary hypertension. Blood Press 1994; 3: 389 – 93. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.